20 December 2018
Measuring the return from pharmaceutical innovation 2018
The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. However, there are opportunities to reverse this trend, which will require new ways of working and a complete digital transformation to unlock R&D productivity and deliver the next generation of scientific breakthroughs.
This ninth annual study by the Deloitte Centre for Health Solutions analyses the return on investment that 12 large cap biopharma companies expect to achieve from their late-stage pipelines, along with four smaller, more specialised companies for comparison. As well as the core analysis, the report also provides recommendations of how the future of work, who does it, and where it gets done, can help companies to unlock R&D productivity.
Key findings for top 12 biopharma companies
The extension cohort of smaller, more specialised companies also saw projected returns drop this year, from 12.5 per cent in 2017 to 9.3 per cent in 2018. This fall was driven by the commercialisation of five major drugs in 2018. However, these smaller firms continue to outperform their peers, finding success in releasing high value products. These products have added $70 billion of projected lifetime sales to the commercial portfolio across the four companies. The extension cohort have also increased their forecast peak sales per asset from $952 million in 2013 to $1,165 million in 2018.
Companies need to act now and embrace new ways of working, embed new technologies and seek out talent with the right skill sets to maximise their return on investment in pharmaceutical innovation.
Our recommendations cover three main focus areas for transformation: technology, collaboration and geography, underpinned by a strong leadership response.
Increased use of automation, natural language processing (NLP) and other cognitive technologies can improve the speed, accuracy and quality of repetitive tasks. This can free up personnel to work on more value-added activities, such as interpretation of results. Implementation and effective application of these technologies requires a shift in workforce skills in order to realise the potential business value.
Companies should look beyond their traditional partnership groups to increase trust and broaden access to patients, and create new operating models to support expansion of more innovative research networks. Working with other groups on collaborative, adaptive clinical studies that allow for simultaneousevaluation of multiple treatments can benefit patients and other stakeholders within a complex trial landscape.
For the biopharma industry, hubs have been a long established idea, but adoption has been limited. To support biopharma companies in their transformation, further geographic clustering can help increase access to external talent and ideas. As well as partnering with technology companies, collaboration with major universities and other developers of pharmaceuticals, medical devices and digital health technologies can be beneficial.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024
Microbial burden assessment of solid pharmaceutical products
22 April 2024
Seasonal variation of microbial contamination in pharmaceutical cleanrooms
22 April 2024